Pricing Log in Create free account
Saturday 17 October 2026 Export JNJ’s income statement to Excel — free account

Johnson & Johnson

JNJ Healthcare Drug Manufacturers General

Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024. In the quarter to September 2026, revenue grew 5.86%, EPS was flat, free cash flow grew 154.8% and total debt fell 4.82%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for three, operating cash flow growth for three; insiders bought in the last twelve months.

255.55 2.27 +0.90%
Market cap
$610.4B
P/E
29.6×
Fwd P/E
24.9×
Dividend yield
2.07%
F-score
3/9
Altman Z
4.78
Beneish M
−2.26
Dividend safety
78/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Johnson & Johnson (JNJ) EV/EBITDA

Alert me on EV/EBITDA

As of 16 October 2026, Johnson & Johnson (JNJ) trades at a EV/EBITDA of 18.1×. Over the past ten years it has ranged from 9.2× (August 2015) to 21.3× (April 2023); the current reading is higher than 90% of that period. That is above the Drug Manufacturers General industry median of 13.8× and above the Healthcare sector median of 9.2×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 12.3× (9.41%)
FY2024 13.6× (18.31%)
FY2023 16.6× (4.74%)
FY2022 17.4× 4.16%
FY2021 16.7× (4.60%)
FY2020 17.5× 11.65%
FY2019 15.7× 17.82%
FY2018 13.3× (15.14%)
FY2017 15.7× 30.18%
FY2016 12.1× 10.03%

Quarterly newest first

Period EV/EBITDA Change
Sep 2026 18.8× 4.13%
Jun 2026 18.0× 3.32%
Mar 2026 17.4× 41.82%
Dec 2025 12.3× 7.50%
43 more quarters

Against its own ten years

Low 9.2× High 21.3×
Ten-year median 14.7×
Current reading's percentile 90

EV/EBITDA against peers

Company EV/EBITDA
PFE Pfizer Inc. compare 10.8×
AZN AstraZeneca PLC compare 13.8×
NVS Novartis AG compare 14.5×
AMGN Amgen Inc. compare 16.8×
JNJ Johnson & Johnson 18.1×
ABBV AbbVie Inc. compare 22.2×
MRK Merck & Co., Inc. compare 29.5×
LLY Eli Lilly and Company compare 32.7×
GILD Gilead Sciences, Inc. compare 829×
Drug Manufacturers General industry median 13.8×
Healthcare sector median 9.2×
Market median 11.0×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on JNJ